U.S. SEC declares Unilife's Form 10 registration statement effective

Unilife Corporation (Company) (ASX: UNS, Nasdaq: UNIS) today announced that the US Securities and Exchange Commission (SEC) declared the Company's Form 10 registration statement effective, clearing the path for Unilife Corporation's listing on the NASDAQ.

The Company expects trading of Unilife Corporation common stock to commence on NASDAQ on or around February 16, 2010 under the ticker "UNIS".

Alan Shortall, CEO of Unilife, stated, "I would like to thank the Unilife team for the completion of this significant corporate milestone. In particular, I wish to note the important contribution made by the Unilife Finance department, and our Australian and US legal representatives, DLA Phillips Fox and DLA Piper who worked tirelessly to achieve this approval within our projected timeframe.

"Despite severe weather conditions in the eastern portion of the US that caused a shutdown of all Federal Government offices in Washington, DC, and restricted operations in both Pennsylvania and New York City, our team has been able to work co-operatively to complete the work necessary to achieve this result. I must compliment the Unilife team and our advisors for an outstanding effort."

The Company also wishes to advise that by the time trading of Unilife common stock commences on NASDAQ, it will have published on its website (www.unilife.com) a list of Frequently Asked Questions (FAQs) to support shareholders wishing to trade on either the ASX or NASDAQ. The Company has also now opened an Investor Hotline to assist with shareholder enquiries during this period. The enquiry line numbers are 1800 632 680 (Australia toll free), +1 866 496 5819 (US toll free) and or +61 2 8256 3394 (International).

SOURCE Unilife Corporation

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.